CIK 0001728117 · Non-accelerated filer<br>Smaller reporting company
Gossamer Bio, Inc.
Sign in to watch- Ticker
- GOSS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 475461709
- Phone
- (858) 684-1300
- Business address
- 3115 MERRYFIELD ROW, SUITE 120, SAN DIEGO, CA, 92121
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +157,500 | 157,500 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +126,667 | 126,667 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +22,784 | 22,784 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +9,167 | 9,167 | ||
| 2026-03-19 | Aranda Richard Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −506,250 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −440,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −375,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −125,000 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −157,500 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −126,667 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −21,167 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −18,834 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −22,784 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −9,167 | 0 | ||
| 2026-03-19 | Peterson Caryn EVP, Regulatory Affairs | Returned to the company · Stock Option (Right to Buy) | −32,334 | 0 |
Page 3 of 14 · 262 trades